Search

Your search keyword '"Boucher, C"' showing total 15 results

Search Constraints

Start Over You searched for: Author "Boucher, C" Remove constraint Author: "Boucher, C" Journal journal of infectious diseases Remove constraint Journal: journal of infectious diseases
15 results on '"Boucher, C"'

Search Results

3. Zidovudine and Interferon- Combination Therapy versus Zidovudine Monotherapy in Subjects with Symptomatic Human Immunodeficiency Virus Type 1 Infection

4. Alternating Nevirapine and Zidovudine Treatment of Human Immunodeficiency Virus Type 1-Infected Persons Does Not Prolong Nevirapine Activity

6. Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients.

7. Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection.

8. High-Dose Nevirapine in Previously Untreated Human Immunodeficiency Virus Type 1-Infected Persons Does Not Result in Sustained Suppression of Viral Replication.

9. Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection.

10. Regional Challenges in the Prevention of Human Immunodeficiency Virus Drug Resistance.

11. Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333.

12. Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333.

13. Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection.

14. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.

15. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.

Catalog

Books, media, physical & digital resources